Travere Therapeutics Stock Forecast, Price & News

Travere Therapeutics (NASDAQ:TVTX) Frequently Asked Questions

Is Travere Therapeutics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Travere Therapeutics stock.
View analyst ratings for Travere Therapeutics or view top-rated stocks.

When is Travere Therapeutics' next earnings date?

Travere Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Travere Therapeutics.

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:TVTX) released its earnings results on Thursday, October, 28th. The company reported ($0.59) EPS for the quarter, beating the Zacks' consensus estimate of ($0.72) by $0.13. The business earned $68.20 million during the quarter, compared to analysts' expectations of $60.93 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 82.45% and a negative net margin of 113.07%. The company's revenue was up 33.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.44) EPS.
View Travere Therapeutics' earnings history.

What price target have analysts set for TVTX?

6 equities research analysts have issued 1-year price objectives for Travere Therapeutics' stock. Their forecasts range from $19.00 to $42.00. On average, they expect Travere Therapeutics' stock price to reach $32.17 in the next year. This suggests a possible upside of 12.7% from the stock's current price.
View analysts' price targets for Travere Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Travere Therapeutics' key executives?

Travere Therapeutics' management team includes the following people:

• Eric M. Dube, President, Chief Executive Officer & Director (LinkedIn Profile)
• Laura M. Clague, Chief Financial Officer
• Bill Rote, Senior VP, Head-Research & Development
• Noah L. Rosenberg, Chief Medical Officer (LinkedIn Profile)
• Elizabeth E. Reed, Secretary, Senior Vice President & General Counsel

Who are some of Travere Therapeutics' key competitors?

Some companies that are related to Travere Therapeutics include Zai Lab (ZLAB), BridgeBio Pharma (BBIO), HUTCHMED (HCM), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Perrigo (PRGO), Mawson Infrastructure Group (WIZP), I-Mab (IMAB), Cerevel Therapeutics (CERE), Allakos (ALLK), Arvinas (ARVN), Karuna Therapeutics (KRTX), Ionis Pharmaceuticals (IONS), Zentalis Pharmaceuticals (ZNTL) and Apellis Pharmaceuticals (APLS).
View all of TVTX's competitors.

What is Travere Therapeutics' stock symbol?

Travere Therapeutics trades on the NASDAQ under the ticker symbol "TVTX."

Who are Travere Therapeutics' major shareholders?

Travere Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (6.57%), VR Adviser LLC (2.83%), Renaissance Technologies LLC (2.03%), Geode Capital Management LLC (1.61%), Dimensional Fund Advisors LP (1.59%) and Laurion Capital Management LP (1.24%). Company insiders that own Travere Therapeutics stock include Elizabeth E Reed, Eric M Dube, Laura Clague, Noah L Rosenberg, Noah L Rosenberg, Noah L Rosenberg, Peter Heerma, Steve Aselage and William E Rote.
View institutional ownership trends for Travere Therapeutics.

Which major investors are selling Travere Therapeutics stock?

TVTX stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Renaissance Technologies LLC, Great Point Partners LLC, Dimensional Fund Advisors LP, Cubist Systematic Strategies LLC, Pura Vida Investments LLC, Squarepoint Ops LLC, and Jane Street Group LLC. Company insiders that have sold Travere Therapeutics company stock in the last year include Elizabeth E Reed, Eric M Dube, Laura Clague, Noah L Rosenberg, Peter Heerma, Steve Aselage, and William E Rote.
View insider buying and selling activity for Travere Therapeutics or view top insider-selling stocks.

Which major investors are buying Travere Therapeutics stock?

TVTX stock was bought by a variety of institutional investors in the last quarter, including VR Adviser LLC, International Biotechnology Trust PLC, BioImpact Capital LLC, Thrivent Financial for Lutherans, Polar Asset Management Partners Inc., Laurion Capital Management LP, Connor Clark & Lunn Investment Management Ltd., and Millennium Management LLC.
View insider buying and selling activity for Travere Therapeutics or or view top insider-buying stocks.

How do I buy shares of Travere Therapeutics?

Shares of TVTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Travere Therapeutics' stock price today?

One share of TVTX stock can currently be purchased for approximately $28.55.

How much money does Travere Therapeutics make?

Travere Therapeutics has a market capitalization of $1.75 billion and generates $198.32 million in revenue each year. The company earns $-169.43 million in net income (profit) each year or ($4.56) on an earnings per share basis.

How many employees does Travere Therapeutics have?

Travere Therapeutics employs 262 workers across the globe.

What is Travere Therapeutics' official website?

The official website for Travere Therapeutics is www.retrophin.com.

Where are Travere Therapeutics' headquarters?

Travere Therapeutics is headquartered at 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130.

How can I contact Travere Therapeutics?

Travere Therapeutics' mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The company can be reached via phone at (888) 969-7879, via email at [email protected], or via fax at 302-645-1280.